SCHEMBL757679

SCHEMBL757679

CCCCCCCCCCCCOCC(COP)OCCCCCCCCCCCC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 9/20 0.58
LPAR3 Q9UBY5 9/20 0.58
LPAR2 Q9HBW0 6/20 0.58
DNM1 Q05193 1/20 0.50
USP2 O75604 1/20 0.47
TLR2 O60603 4/20 0.47
HTT P42858 1/20 0.46
PRKD3 O94806 1/20 0.45
PRKCG P05129 1/20 0.45
PRKCB P05771 1/20 0.45
PRKCA P17252 1/20 0.45
PRKCH P24723 1/20 0.45
PRKCI P41743 1/20 0.45
PRKCE Q02156 1/20 0.45
PRKCQ Q04759 1/20 0.45
PRKCZ Q05513 1/20 0.45
PRKCD Q05655 1/20 0.45
PRKD1 Q15139 1/20 0.45
LPAR6 P43657 5/20 0.44
LPAR4 Q99677 5/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL226510 1.00 LPAR1 (0.58) LPAR1LPAR3LPAR2DNM1USP2
SCHEMBL1804845 1.00 LPAR1 (0.58) LPAR1LPAR3LPAR2DNM1USP2
SCHEMBL2517959 1.00 LPAR1 (0.58) LPAR1LPAR3LPAR2DNM1USP2
SCHEMBL4794837 1.00 LPAR1 (0.58) LPAR1LPAR3LPAR2DNM1USP2
SCHEMBL1081182 0.90 ALDH1A1 (0.53) LPAR1LPAR3LPAR2
SCHEMBL303128 0.90 LPAR1 (0.68) LPAR1LPAR3LPAR2DNM1USP2
SCHEMBL4204833 0.90 LPAR1 (0.68) LPAR1LPAR3LPAR2DNM1USP2
SCHEMBL8636551 0.90 LPAR1 (0.68) LPAR1LPAR3LPAR2DNM1USP2
SCHEMBL4879843 0.90 LPAR1 (0.68) LPAR1LPAR3LPAR2DNM1USP2
SCHEMBL4294185 0.90 LPAR1 (0.68) LPAR1LPAR3LPAR2DNM1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113840624-A Monosaccharide-labeled nanoliposome drug delivery system, preparation method thereof and application thereof as drug targeting delivery carrier 法玛科技顾问股份有限公司 2021-12-24 CN claimed
WO-2020232701-A1 MONOSACCHARIDE LABELED NANOLIPOSOME DRUG DELIVERY SYSTEM, PREPARATION METHOD THEREFOR AND USE OF SAME AS TARGETING DELIVERY VECTOR FOR DRUG 法玛科技顾问股份有限公司 (CN) 2020-11-26 WO claimed
EP-3673899-A1 NASAL POWDER FORMULATION FOR TREATMENT OF HYPOGLYCEMIA ELI LILLY AND CO. (US) 2020-07-01 EP claimed
EP-3673900-A1 NASAL POWDER FORMULATION FOR TREATMENT OF HYPOGLYCEMIA ELI LILLY AND CO. (US) 2020-07-01 EP claimed
US-20180104238-A9 Method And Composition For Treating Rhinitis BIOLIPOX AB (SE) 2018-04-19 US claimed
US-20170202775-A1 METHOD FOR PREPARATION OF LIPID BUBBLES SOUTHEAST UNIVERSITY (CN) 2017-07-20 US claimed
US-20160166508-A1 Method and Composition for Treating Inflammatory Disorders MEDA AB (SE) 2016-06-16 US claimed
EP-1919450-B1 ANTIHISTAMINE- AND CORTICOSTEROID-CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS MEDA AB (SE) 2014-06-11 EP claimed
US-20140065203-A1 ANTIHISTAMINE- AND CORTICOSTEROID-CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS BIOLIPOX AB (SE) 2014-03-06 US claimed
EP-1888033-B1 METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS MEDA AB (SE) 2014-02-19 EP claimed
US-5874104-A ALSO CONTAINING CHOLESTEROL; HYDRATED IN AQUEOUS MONO- OR DISACCHARIDE; STORAGE STABILITY NEXSTAR PHARMACEUTICALS, INC. (US) 1999-02-23 US claimed
US-5759571-A AMINOGLYCOSIDE ENCAPSULATED IN LIPOSOMES OF CHOLESTEROL AND LIPIDS NEXSTAR PHARMACEUTICALS, INC. (US) 1998-06-02 US claimed
US-5756121-A FORMING LIPOSOMES FOR TREATMENT OF DRUG RESISTANT BACTERIA NEXSTAR PHARMACEUTICALS, INC. (US) 1998-05-26 US claimed
US-5756120-A CONTAINING LIPID AND STEROL NEXSTAR PHARMACEUTICALS, INC. (US) 1998-05-26 US claimed
US-5688525-A LIPOSOMES AND LIPIDS WITH CHOLESTEROL AND CYCLOSPORIN NEXSTAR PHARMACEUTICALS, INC. (US) 1997-11-18 US claimed
EP-0580817-B1 PHARMACEUTICAL FORMULATION AND PROCESS NEXSTAR PHARMACEUTICALS INC (US) 1996-06-19 EP claimed
EP-0580817-A1 PHARMACEUTICAL FORMULATION AND PROCESS. VESTAR INC (US) 1994-02-02 EP claimed
WO-1992018104-A1 PHARMACEUTICAL FORMULATION AND PROCESS VESTAR, INC. (US) 1992-10-29 WO claimed
EP-0317120-B1 IMPROVED AMPHOTERICIN B LIPOSOME PREPARATION VESTAR, INC. (US) 1991-08-28 EP claimed
EP-0317120-A1 Improved amphotericin B liposome preparation VESTAR, INC. (US) 1989-05-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140065203-A1 ANTIHISTAMINE- AND CORTICOSTEROID-CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS HRH1, HRH4, HRH3 LPAR1 17/4885LPAR3 21/4885LPAR2 19/4885
US-20160166508-A1 Method and Composition for Treating Inflammatory Disorders LIPA, HRH2, HRH1 LPAR1 42/4885LPAR3 51/4885LPAR2 31/4885
US-20180104238-A9 Method And Composition For Treating Rhinitis HRH1, HRH2, LIPA LPAR1 12/4885LPAR3 10/4885LPAR2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.